Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
C-CAR039 in Relapsed or Refractory NHL
NCT04317885Phase 1Completed
- Sponsor
- Tongji Hospital
- Start
- Nov 2019
- Primary completion
- Jun 2023
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of prizloncabtagene autoleucel in B-cell non-Hodgkin lymphoma, sponsored by Tongji Hospital. Primary endpoint: Incidence and severity of adverse events at 12 weeks. Started Nov 2019; status: completed.
02
Drugs
prizloncabtagene autoleucel
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT04317885.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04317885.